Health ❯Healthcare

Biotechnology

Biotechnology Clinical Trials Patient Care Stock Market Investments Pharmaceuticals Medical Treatments Medical Research Regulatory Affairs Clinical Research

Eli Lilly to Acquire Verve Therapeutics as Gene-Editing Trial Begins

The $1.3 billion purchase marks a major step in Lilly’s expansion into PCSK9-targeting therapies with closing slated for Q3 2025.

Regencell Shares Soar Again, Market Cap Tops $36 Billion After Stock Split

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

Sarepta Halts Elevidys Shipments for Non-Ambulatory Patients After Second Fatal Liver Failure

Anne Wojcicki’s Nonprofit Wins Bid to Acquire 23andMe for $305 Million

FDA Approves First Eye Implant to Preserve Vision in Rare Macular Telangiectasia

AI-Designed Rentosertib Improves Lung Function in Phase IIa IPF Trial

Next-Generation CAR-T Therapies Deliver Remission in T-Cell Cancers and Extend Survival in Gastric and Brain Tumors

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data

Lotte Biologics Secures First ADC Manufacturing Deal, Launches Full-Scale Operations

Verve-102 Gene-Editing Therapy Shows Promising LDL Cholesterol Reduction in Early Trial

First Death Reported from Sarepta's Duchenne Gene Therapy Raises Safety Concerns

Second Successful Pig Kidney Transplant Offers New Hope for Organ Shortage Crisis